Intradigm lands $18.5M to advance oncology treatment
Intradigm, a biotech company that develops RNA interference treatments for cancer, announced today that it took $18.5 million in a second round of financing that included new investors Lilly Ventures, Roche Venture Fund, MP Healthcare Venture Management, and existing investors Alta Partners, Frazier Healthcare Ventures, MediBic Alliance Technology Fund and Novartis Venture Fund.
The Palo Alto, Calif.-based company has developed an RNA interference therapy for cancer, as well as a mode for delivering it to the right parts of the body. That delivery system is what distinguishes Intradigm from its competitors, includng Sirna Therapeutics Inc., which continues to administer RNA interference therapies locally. It will use this new round of funds to forge partnerships that could move technology and testing forward. It hopes to have a treatment enter the clinical phase of testing by 2010.
Next Story: Zapatec takes on established email solutions with 6zap
Previous Story: Avaak brings in $7M to prep wire-free camera
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.